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Genomic and expression profiling reveal molecular
heterogeneity of disseminated tumor cells in bone marrow of
early breast cancer
Mark Jesus M. Magbanua1, Hope S. Rugo1, Louai Hauranieh1, Ritu Roy2, Janet H. Scott1, Jen Chieh Lee1, Feng Hsiao1, Eduardo V. Sosa1,
Laura van’t Veer3, Laura J. Esserman4 and John W. Park1
Detection of disseminated tumor cells (DTCs) in bone marrow is an established negative prognostic factor. We isolated small pools
of (~20) EPCAM-positive DTCs from early breast cancer patients for genomic profiling. Genome-wide copy number profiles of DTC
pools (n= 45) appeared less aberrant than the corresponding primary tumors (PT, n= 16). PIK3CA mutations were detected in 26%
of DTC pools (n= 53), none of them were shared with matched PTs. Expression profiling of DTC pools (n= 30) confirmed the
upregulation of EPCAM expression and certain oncogenes (e.g., MYC and CCNE1), as well as the absence of hematopoietic features.
Two expression subtypes were observed: (1) luminal with dual epithelial–mesenchymal properties (high ESR1 and VIM/CAV1
expression), and (2) basal-like with proliferative/stem cell-like phenotype (low ESR1 and high MKI67/ALDH1A1 expression). We
observed high discordance between ESR1 (40%) and ERRB2 (43%) expression in DTC pools vs. the clinical ER and HER2 status of the
corresponding primary tumors, suggesting plasticity of biomarker status during dissemination to the bone marrow. Comparison of
expression profiles of DTC pools with available data from circulating tumor cells (CTCs) of metastatic breast cancer patients revealed
gene expression signatures in DTCs that were unique from those of CTCs. For example, ALDH1A1, CAV1, and VIM were upregulated
in DTC pools relative to CTCs. Taken together, analysis of pooled DTCs revealed molecular heterogeneity, possible genetic
divergence from corresponding primary tumor, and two distinct subpopulations. Validation in larger cohorts is needed to confirm
the presence of these molecular subtypes and to evaluate their biological and clinical significance.
npj Breast Cancer  (2018) 4:31 ; doi:10.1038/s41523-018-0083-5
INTRODUCTION
Efforts toward detection and characterization of disseminated
tumor cells (DTC) have been actively pursued to shed light on
their molecular nature and to evaluate their potential clinical
utility as biomarkers.1–3 While many studies have now shown that
the presence of DTCs is strongly associated with poor patient
outcomes,4–6 testing for DTCs has not been incorporated into
standard clinical practice due to a lack of consensus on methods
for detection of these cells.1,7 DTC assays have often relied on
immunocytochemistry or polymerase chain reaction-based meth-
ods to detect the presence of these cells in the bone marrow.1 Our
group has used EPCAM-based immunomagnetic enrichment and
fluorescence-activated cell sorting (IE/FACS) for detection and
isolation of circulating tumor cells (CTC) from blood of cancer
patients.8,9 This method involves an initial IE step using magnetic
beads coated with monoclonal antibody to EPCAM, followed by
FACS to detect and purify CTCs away from blood cells. Previous
studies have demonstrated the robustness of the IE/FACS method
for detection and isolation of highly pure CTCs (>90%),8,9 and
downstream molecular analyses have confirmed the malignant
nature of IE/FACS-isolated CTCs.8–10
In this study, we applied IE/FACS to detect and isolate pools of
EPCAM-expressing DTCs from bone marrow of early breast cancer
patients. Pooled cells, along with their matched primary tumors,
were subjected to genome-wide copy number analysis and PIK3CA
mutation screening. We also analyzed the expression of 64 cancer-
related genes in DTCs, and compared DTC expression profiles with
publicly available CTC gene expression data. Finally, we compared
ESR1 and ERBB2 expression in DTCs vs. the clinical ER and HER
status of corresponding primary tumors.
RESULTS
DTCs can be enumerated by IE/FACS
Bone marrow aspiration was performed in the operating room
immediately prior to breast surgery. Samples were then analyzed
via IE/FACS assay to detect and enumerate DTCs (Fig. 1a). A total
of 71 sequential patients who had detectable DTCs were included
in this study (Fig. 1b, Supplementary Table 1). The median age was
51 years old. 30% of patients were node-positive. 73% of patients
were ER-positive, and 21% were HER2-positive. 41% received
neoadjuvant chemotherapy prior to study entry.
We did not observe any significant correlation between the
concentration of DTCs in the bone marrow (DTC/mL) and standard
clinical and pathologic variables (Fig. 1c, d, Supplementary Fig. 1).
We did observe higher median DTC/mL in patients who received
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neoadjuvant chemotherapy compared to those who were
treatment naive at the time of surgery (Kruskal–Wallis p= 0.048)
(Fig. 1c). Node-positive patients showed a statistically insignificant
trend toward higher median DTC/mL compared to node-negative
patients (Kruskal–Wallis p= 0.177). The patient with the highest
concentration of DTCs (322.8 DTC/mL) also had largest number of
axillary lymph node metastases (21 positive nodes, Fig. 1d).
Molecular characterization of DTCs
After enumeration of DTCs in 4 mLs of bone marrow, the
remaining volume was subjected to IE/FACS to isolate pools of
DTCs. Downstream molecular analysis of pooled DTCs was
performed in overlapping subsets of the 71 patients from whom
DTCs were enumerated and isolated (Supplementary Fig. 2A). A
flow chart showing the number of patients and samples used for
analysis is presented in Supplementary Fig. 2B. DTCs were
subjected to genome-wide copy number analysis, PIK3CA muta-
tion screening, and gene expression analysis of 64 cancer-related
genes. The panel included epithelial and hematopoietic markers,
as well as genes involved in proliferation, tumorigenesis, cell
death, epithelial-to-mesenchymal transition (EMT), and stem cell-
ness (Supplementary Table 2). Results of molecular profiling are
described below.
Fig. 1 DTCs from bone marrow of early breast cancer patients were enumerated and isolated for downstream molecular profiling. a
Enumeration and isolation of DTCs using a two-step process involving immunomagnetic enrichment and flow cytometry or fluorescence-
activated cell sorting (IE/FACS). b Clinical characteristics of 71 patients from whom DTCs were enumerated. Each column represents a patient.
c–d Comparison of DTC/mL between groups based on patient treatment and nodal status (also see Supplementary Fig. 1 for extended
analysis)
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DTCs appear less genomically aberrant than corresponding
primary tumors
Pools of DTCs were isolated from 56 of 71 patients in study (79%).
Forty-five (80%) of these DTC samples were successfully analyzed
by array comparative genomic hybridization (aCGH) (Supplemen-
tary Table 3). Genome-wide copy number profiling of matched
primary tumors (and one lymph node metastasis) from 16 patients
revealed numerous aberrations, including those frequently found
in primary breast tumors (e.g., 1q gain, 8p loss, 8q gain, and 16q
loss)11 (Fig. 2a). DTCs, in general, displayed fewer copy number
alterations than the primary tumors (Fig. 2b). Overall, the fraction
of genome altered in DTCs was significantly lower compared to
that of primary tumors (linear regression (LR) p= 0.0019), and so
were the fractions of genome gained (LR p= 0.0032) and lost (LR
p= 0.0079). Representative DTC and primary tumor pairs are
shown in Supplementary Fig. 3A. Comparative analysis of genomic
aberrations between the two groups revealed a significantly
higher proportion of primary tumors with 14q12–q21 gain
(adjusted p= 0.007) and 16q12 loss (adjusted p= 0.007) (Supple-
mentary Fig. 3B). Unsupervised hierarchical clustering revealed
two major clusters and a singleton DTC sample (Fig. 2c). The left
cluster contained mostly DTCs, while the right cluster contained
DTC and primary tumor samples. Visual inspection of the heatmap
revealed that the loss of chromosome 19, which was observed
predominantly in the right cluster, appeared to drive cluster
separation. Interestingly, none of the 16 DTC and primary tumor
Fig. 2 DTCs appear to have less genomic aberrations vs. matched primary tumors. a Frequency plot of clone-wise comparisons of archival
tumors available from 16 patients (15 primary tumors and 1 lymph node) vs. DTCs (n= 45). Red and blue horizontal lines depict frequency of
gain and loss, respectively. b Comparison of the extent of genomic aberrations in DTCs vs. primary tumors (PT). The p-values shown were
calculated from fitting a linear model with the log-transformed fraction of genome gained (or lost or altered) as the response variable and
sample type as the predictor variable along with patient ID as a covariate. c Heatmap based on gain/loss status using Euclidean distance and
Ward agglomeration method. Columns represent samples. Chromosomes 1–22 are ordered from bottom to top (rows). Red, blue, and yellow
dots represent gain, loss, and amplification, respectively. The yellow box indicates loss of chromosome 19, which is observed predominantly in
the right cluster, and appears to drive cluster separation
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pairs clustered together. Taken together, these results indicate
significant divergence of copy number profiles in DTCs as
compared with those of the matched primary tumor, and suggest
that DTCs generally contain fewer genomic abnormalities than the
primary tumor.
DTCs show frequent PIK3CA mutation
Next, we screened for PIK3CA “hotspot” mutations in 55 of the 56
DTC samples previously analyzed by aCGH. Both Exons 9 and 20 of
PIK3CA, which includes the mutational hotspots E545 and H1047,
respectively, were sequenced (Supplementary Fig. 4). Testing in
cell lines with known mutation status revealed specificity of the
assay (Fig. 3a). Fifty-three patients had evaluable sequencing data
(Supplementary Table 4). Of those, 19 mutations (8 in exon 9 and
11 in exon 20) were detected in DTCs from 14 (26%) of the 53
patients with evaluable sequencing data (Fig. 3b, c). These
included 3 silent, 2 frameshift, 2 nonsense, and 12 missense
mutations. One of the silent mutations was considered germline,
while the rest were not observed in corresponding normal marrow
leukocytes. Eleven of the 19 (58%) have been previously reported
in the COSMIC and/or TCGA databases, and 15 (80%) were
predicted to be pathogenic or probably damaging. In matched
archival samples, three primary tumors and the lymph node
metastasis (29%) carried PIK3CA mutations. No PIK3CA mutations
were shared between DTCs and matched primary tumors.
Fig. 3 PIK3CA mutations can be detected in DTCs. a Sanger sequencing traces from cell lines used for assay optimization. Positive controls,
MCF7 and BT20 carry mutations E545K (Exon 9) and H1047R (Exon 20), respectively, but not the negative control BT474 cells. b Representative
Sanger sequencing traces depicting mutations detected in DTCs from five patients. c Summary of sequencing data from DTCs, primary
tumors, and a lymph node (LN) with at least one mutation detected. The complete list of patients screened for PIK3CA mutations and
corresponding sequencing results are found in Supplementary Table 4
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Expression profiling of IE/FACS-isolated DTCs indicate epithelial
and malignant origin
We isolated pools of DTCs from 35 of the 71 patients in the study
(49%), 30 (86%) of whom were successfully subjected to multi-
plexed Taqman Low-Density Array QPCR (aQPCR) analysis of 64
cancer-related genes (Supplementary Table 5). In parallel, marrow
leukocytes from 15 patients were isolated and profiled. Compar-
ison of DTC expression profiles with marrow leukocytes revealed
significant upregulation of EPCAM and MUC1, and downregulation
of hematopoietic cell markers, PTPRC/CD45 and CD68 (Fig. 4a).
These results are consistent with our epithelial-based approach for
isolation of DTCs. Moreover, oncogenes CCNE1 and MYC were also
upregulated in DTCs.
Of the 30 patients whose DTCs were successfully analyzed by
aQPCR, 14 had corresponding PIK3CA mutation data, 4 (29%) of
whom carried non-synonymous PIK3CAmutations (Supplementary
Fig. 2C). Taken together, the detection of PIK3CA mutations and
the upregulation of oncogenes CCNE1 and MYC in DTCs suggest
malignant phenotype.
Expression profiling reveals two distinct groups of DTCs
Unsupervised hierarchical clustering analysis revealed two major
clusters: a cluster containing only DTCs (DTC cluster 1, n= 14), and
another cluster which contained both DTCs (DTC cluster 2, n= 16)
and marrow leukocytes (Fig. 4b). Differential expression analysis
revealed that DTCs in each cluster showed significant upregula-
tion of EPCAM and downregulation of PTPRC relative to marrow
leukocytes (Supplementary Fig. 5), confirming their epithelial and
non-hematopoietic nature.
Next, we compared the expression profiles of the two DTC
clusters. Upregulated genes in DTC cluster 1 relative to cluster 2
(Fig. 4c), included cell proliferation and cancer stem cell-associated
Fig. 4 Gene expression analysis reveals two groups of DTCs with distinct expression profiles. a Volcano plot showing differentially expressed
genes between DTCs and marrow leukocytes. Genes with an adjusted p-value < 0.05 (black dashed line) were considered statistically
significant. Relative quantification (RQ) is reported in the logarithmic scale (log10 RQ= log10^2-ΔΔCT). A Log10 RQ= 1 or −1 means a gene is
expressed 10 times or 1/10 as much, respectively, in DTCs relative to marrow leukocyte samples. b Unsupervised hierarchical clustering
analysis of DTCs (n= 30) and CD45-positive marrow leukocytes (n= 15) isolated by IE/FACS. c A rose plot showing genes upregulated in DTCs
in cluster 1 (yellow) and cluster 2 (blue). d Violin plot of the 21-gene recurrence scores derived from DTC gene expression data from aQPCR
analysis. The red line indicates the median. e Kaplan–Meier analysis for recurrence-free survival between patients whose DTCs belong to
cluster 1 vs. cluster 2
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genes. For example, upregulated genes included MKI67, a
proliferation marker; ALDH1A1, a cancer stem cell marker;12 and
TACC3, a gene associated with stemness and proliferation.13,14
Proliferation-related genes CCNB115 and MYBL216 were also
upregulated, as was TFRC, a gene known to be overexpressed in
proliferating malignant cells.17 MUC1, an epithelial and breast
cancer marker, was upregulated in this cluster.
Genes upregulated in DTC cluster 2 relative to cluster 1 included
ESR1, which encodes the estrogen receptor; CAV1, a regulator of
estrogen-dependent signaling;18 and BCL2, an anti-apoptotic gene
associated with estrogen receptor positivity.19 Interestingly, the
macrophage marker CD68 was also upregulated. CD24, a gene
that is usually downregulated in cancer stem cell marker was
upregulated.20 Other genes that were upregulated included
epithelial cytokeratins, KRT18, KRT19, KRT6A, and KRT6B, as well
as VIM1, a mesenchymal marker.21 Other upregulated genes
include SPARC (osteonectin), a gene associated with EMT,22 and
bone metastasis,23 and CAPG, a putative biomarker for bone
metastasis.24
The aQPCR assay included a 21-gene signature (Oncotype Dx),25
which allows for the calculation of recurrence scores (RS,
Supplementary Information). When RS was calculated in our DTC
samples (n= 30), all samples were classified in the high-risk group
(RS ≥ 31) (Fig. 4d). We observed a slight trend toward higher RSs
for samples in DTC cluster 1 compared to those in DTC cluster 2,
but this was not statistically significant (Mann–Whitney U p=
0.1285).
Clinical follow-up revealed that two patients in cluster 1
experienced recurrence (bone and lymph node metastasis,
respectively). In cluster 2, one patient developed liver metastasis.
With a median follow-up of 58 months, the difference in distant
recurrence-free survival between groups was not statistically
significant (log-rank p= 0.32) (Fig. 4e).
ESR1/ER and ERBB2/HER2 status in DTCs vs. matched primary
tumors show high discordance
We used gene expression data to assign ESR1 and ERBB2 status in
30 DTC samples (Supplementary Information). Detectable expres-
sion (Ct < 36) was considered positive. We also calculated relative
ESR1 and ERBB2 (LogRQ10) expression in a subset of DTC samples
with corresponding marrow leukocytes (n= 15). Using breast
cancer cell lines with known ER (Fig. 5a) and HER2 (Fig. 5b) status
as references, a Log10 RQ ≥ 1 was considered positive. Both
approaches (Ct < 36 or Log10 RQ ≥ 1) showed high agreement in
calls for ESR1 (93%) and ERBB2 (87%) expression status.
Based on detectable expression (Ct < 36), 53% (16 of 30) of the
DTCs were ESR1-positive and 27% (8 of 30) were ERBB2-positive
(Supplementary Fig. 6A). Interestingly, aCGH analysis did not
detect gains or amplification of the ERBB2 locus in any of DTC
samples analyzed (data not shown). Cluster 2 contained a
significantly higher proportion of ER-positive DTCs compared to
cluster 1 (75 vs. 29%, Chi-squared p= 0.0132). In contrast, cluster 1
contained a higher proportion of HER2-positive DTCs compared to
cluster 2 (43 vs. 13%), but was not statistically significant (Chi-
squared p= 0.0695).
Of the 30 DTC samples profiled, matching primary tumor clinical
results for ER (n= 29) and HER2 (n= 28) were available. 86% of
the primary tumors were ER-positive, and 25% were HER2-positive.
Eleven of the 25 (44%) ER-positive primary tumor samples were
Fig. 5 ESR1/ER and ERBB2/HER2 status in DTCs and matched primary tumors show high discordance. a ESR1 and b ERBB2 expression in DTCs
and breast cancer cell lines with known ER and HER2 status, respectively. The red dashed lines indicate the selected cut-off for positivity
(Log10 RQ= 1); two-by-two contingency tables showing agreement in c ESR1 and ER status and d ERBB2 and HER2 status in DTCs vs. matched
primary tumors
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associated with ESR1-negative DTCs, while 2 of the 4 (50%) ER-
negative tumors had ER-positive DTCs (Fig. 5c). All 7 patients with
HER2-positive primary tumors had HER2-negative DTCs, while 5 of
the 21 (24%) HER2-negative patients had HER2-positive DTCs (Fig.
5d). Overall, the discordance in ER and HER2 status between DTCs
and their corresponding primary tumors was high (45%, κ= 0.031
and 43%, κ=−0.263, respectively).
The proportion of receptor subtypes was significantly different
between DTCs and primary tumors (Fisher’s exact p= 0.028)
(Supplementary Fig. 6B). ESR1−ERBB2+ and ESR1−ERBB2− sub-
types were more frequent in DTCs, while ER+HER2− and ER
−HER2+ subtypes were more frequent in primary tumors. The ER
−HER2+ subtype was not represented among the matched
primary tumors in this cohort.
DTC gene expression and neoadjuvant treatment
Fifteen of the 30 patients with DTC expression data had
completed neoadjuvant chemotherapy at the time of bone
marrow aspiration. Expression profiles of DTCs did not appear to
cluster based on whether neoadjuvant treatment was received
(Supplementary Fig. 6A). Differential expression analysis between
DTCs from treatment-naive vs. neoadjuvant-treated patients did
not show significant differentially expressed genes (Supplemen-
tary Fig. 6C).
DTC gene expression profiles appear different from those of CTCs
Next, we compared expression profiles of DTCs with CTC gene
expression data recently reported by our group.9 In a previous
study, CTCs were isolated from blood of metastatic breast cancer
patients using the same IE/FACS method, and profiled using the
same microfluidic aQPCR platform. The merged data was normal-
ized using the reference genes (RPS18 and ACTB).
Unsupervised hierarchical clustering of CTCs (n= 105), DTCs (n
= 30), blood (n= 76), and bone marrow leukocytes (n= 15)
revealed four major clusters (Fig. 6a). The first cluster, which
formed an entirely separate group, contained identical DTC
samples from previously identified cluster 1. The second cluster
contained samples that were predominantly CTCs. The third
cluster contained a combination of blood and marrow leukocytes.
The fourth cluster had seven subclusters, each with mostly the
same cell types. Subcluster 6, for example, contained all but one of
the DTC samples belonging to the previously identified cluster 2.
Two-dimensional t-SNE analysis to identify clusters revealed
similar results (Fig. 6b). In general, bone marrow and blood
leukocytes clustered together, while CTCs formed a separate
cluster. Moreover, DTC samples separated into two groups
corresponding to the clusters identified above.
Differential expression analysis revealed that, relative to DTCs,
CTCs exhibit upregulation of epithelial (KRT7, KRT19, MUC1) and
EMT (SNAI1) markers; upregulation of the androgen receptor (AR),
estrogen-related genes (ESR1, AGR2, SCUBE2, SCGB2A2, SCGB2A1,
TFF1, TFF3), as well as HER2-related genes (ERBB2, GRB7) (Fig. 6c).
DTCs, on the other hand, displayed upregulation of mesenchymal
(VIM) and epithelial markers (KRT6A, KRT6B, KRT18), and putative
stem cell marker ALDH1A1.
DISCUSSION
Improvements in technologies for rare-cell detection and analysis
of limited amount of nucleic acids in the past two decades have
facilitated efforts toward isolation and molecular characterization
Fig. 6 DTCs and CTCs exhibit expression profiles that are unique from each other. a Unsupervised hierarchical clustering analysis of CTCs (n=
105) and DTCs (n= 30) along with matched blood leukocytes (n= 76) and marrow leukocytes (n= 15). b t-SNE analysis to determine clusters
based on similarities in gene expression. c A rose plot showing genes upregulated in DTCs and CTCs. Genes with an adjusted p-value < 0.05
were considered statistically significant. Relative quantification (RQ) is reported in the logarithmic scale (log10 RQ= log10^2-ΔΔCT). A Log10
RQ= 1 or −1 means a gene is expressed 10 times or 1/10 as much, respectively
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of DTCs.26–44 Evidence from early genomic studies of DTCs have
provided insights into mechanisms of cancer dissemination and
evolution1 (also see Supplementary Table 6). We built upon these
previous studies by performing copy number, gene expression,
and mutation screening in EPCAM-positive DTCs detected in bone
marrow of early breast cancer patients. Our results revealed
genomic heterogeneity and malignant characteristics in these
cells. We also detected two subpopulations of DTCs with differing
phenotypic properties.
Approaches for detection of DTCs have frequently relied on
immunophenotyping to identify epithelial cells in the bone
marrow. Borgen and colleagues45 previously outlined a standar-
dized immunocytochemical (ICC) method for detection of micro-
metastatic cells using pan-cytokeratin (CK) monoclonal antibodies
along with morphological criteria to classify cells positive for
cytokeratin staining.
In this study, we demonstrated the feasibility of an EPCAM-
based approach for detection and isolation of DTCs.9 We utilized
the cell surface marker EPCAM because it obviated the need for
harsh permeabilization (required to access cytoplasmic CK
antigens), a procedure that could potentially affect nucleic acid
stability.46 In addition, EPCAM-based cell capture has been used
extensively for CTCs,47 and so by isolating DTCs with a parallel
approach we could directly compare cancer cells from these two
compartments. Similar to CK-based detection, positive EPCAM
expression is not a sufficient criterion to consider a cell a cancer
cell. Here, we provide molecular evidence that EPCAM-positive
cells isolated via IE/FACS from the bone marrow display molecular
features that are consistent with a tumor phenotype.
The IE/FACS approach used here was able to recover relatively
high numbers of DTCs for analysis. What appears to be a high
number of DTCs isolated by IE/FACS in comparison to standard
ICC reflects the number of cells analyzed in each assay. The
standard ICC assay for DTC detection typically evaluates 4–8
million mononuclear cells per sample. For example, Fehm and
colleagues outlined a standardized ICC protocol involving
cytospins of Ficoll-separated mononuclear cells onto 2–4 slides
(each containing 2 million mononuclear cells).48 In contrast, the IE/
FACS assay, which routinely utilizes 4 mL of bone marrow,
analyzes ~176 million mononuclear cells per sample, a 20-fold
or more larger number of cells. On the other hand, the higher
sensitivity of IE/FACS is accompanied by lower specificity than
standard ICC. In separate larger scale studies, we observed that
68% of bone marrow samples from 584 early breast cancer
patients were considered positive for DTCs (Magbanua, in
preparation). This is clearly higher than the positivity rate of
30.6% reported in a large pooled analysis of ICC-based studies.5
Our genome-wide copy number analysis revealed that DTCs, in
general, carried fewer aberrations than the matched primary
tumors. These results are consistent with previous studies
indicating lesser genomic changes in DTCs vs. primary
tumor.26,29,31,34,37,41,49 For example, Klein and colleagues isolated
DTCs based on CK26,27 and EPCAM28 expression, and developed a
method for genomic profiling of single cells using chromosome
comparative genomic hybridization (cCGH) analysis. Single cell
studies by Klein et al.26 revealed fewer copy number aberrations in
DTCs from non-metastatic patients compared to those from
patients with metastatic disease. Using the same cCGH method,
Schumacher and colleagues35 recently reported on copy number
analysis in single CK-positive DTCs from patients with non-
metastatic esophageal cancer. These investigators also observed
that DTCs had fewer aberrations compared to corresponding
primary tumors. Detection of genomic aberrancy in DTCs in these
studies may have been limited by the low resolution of the cCGH
method, which makes it less sensitive in detecting small copy
number aberrations.50 However, Holcomb and colleagues49 used
high-resolution array-based CGH analysis in small pools of EPCAM-
positive DTCs; they reported that cells isolated from patients with
localized prostate cancer had significantly fewer aberrations vs.
their corresponding primary tumors.49
Alternatively, our results showing relatively lower copy number
variations in DTCs may be at least in part attributable to the
presence of non-DTCs within the pools analyzed by aCGH. Indeed,
one of the major limitations of this study is that cells were
analyzed as pools and not as individual cells, thus preventing the
examination of copy number profiles at the single cell level. Single
cell genomic analysis of CK-positive cells in the bone marrow by
Demeulemeester and colleagues32 revealed that 53% (10 of 19) of
these cells were in fact DTCs, with tumor-specific genomic
aberrations consistent with those found in the corresponding
primary tumors.32 The remaining cells initially classified as tumor
cells were found to be “normal” cells (30%) or “aberrant cells of
unknown origin” (16%). The authors hypothesized that these non-
DTC cells were nonmalignant epithelial cells, hematopoietic
lineage cells, or actual tumor cells from an unrelated cancer.
Sequence analysis of PIK3CA revealed that about quarter of
DTCs carry genetic alterations in this gene. These included novel
mutations and those that have been previously documented in
breast and other cancers.11,51 Some DTCs carried mutations in the
PIK3CA hot spots, e.g., E545D/G on Exon 9 and H1047R on Exon
20.11 Interestingly, the mutations detected in DTCs were not
present in the corresponding primary tumors. Other studies have
also detected PIK3CA mutations in CTCs and DTCs that were not
found in their corresponding primary tumors.52–54
Consistent with our epithelial-based isolation strategy, we
observed upregulation of EPCAM and downregulation of PTPRC
in DTCs. Unsupervised clustering analysis revealed two groups of
DTCs with distinct expression profiles. Furthermore, comparisons
of expression profiles of DTCs in each cluster with those of marrow
leukocytes confirmed upregulation of EPCAM and downregulation
of PTPRC. While CD68, a macrophage-specific marker, was overall
downregulated in DTCs relative to marrow leukocytes, differential
expression analysis between the two DTC clusters showed that
DTCs in cluster 2 displayed significantly higher expression levels of
CD68 compared to those in cluster 1. It is possible that DTC
samples in cluster 2 had macrophage contamination. However,
evidence showing that PTPRC—a pan-leukocyte marker also
expressed in macrophages—was not differentially expressed
between the two groups does not support this assumption.
Lustberg and colleagues55 observed atypical CK-positive CTCs in
blood of metastatic breast cancer patients that also expressed
CD68. DTCs in cluster 2 may be enriched for these atypical double
positive cells. Furthermore, Adam and colleagues56 observed that
circulating-associated macrophage-like cells (CAML) physically
interact with CTCs in circulation to facilitate tumor dissemination.
It is tempting to speculate that CD68 signals observed in DTC
cluster 2 may be coming from CAML cells co-isolated with DTCs.
Nonetheless, the upregulation of CD68 in this DTC cluster warrants
further investigation.
Analysis using the 21-gene signature revealed that DTCs in
cluster 1 have a numerically higher median RS than those in
cluster 2. These results are consistent with gene expression data
showing that DTCs in the cluster 1 may have a more aggressive
phenotype as they exhibited basal-like (low ESR1), proliferative
(high MKI67), and stem cell-like (high ALDH1A1) characteristics.
DTCs in cluster 2, in contrast, displayed luminal phenotype (high
ESR1), low proliferative potential (low MKI67), and dual
epithelial–mesenchymal characteristics (high EPCAM and VIM
expression), and may represent a less aggressive subtype of DTCs.
Sosa and colleagues have proposed that early during the
disease process DTCs transit to niches that either promote tumor
dormancy (Ki67-negative DTCs) or proliferative growth (Ki67-
positive DTCs).57 It is possible that the DTC subtypes observed in
this study represent these two different subpopulations of DTCs.
For example, the upregulation of SPARC (osteonectin), which has
been implicated in metastatic dormancy in bone58 and
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downregulation of MKI67 in DTCs in cluster 2 suggest that these
cells may be dormant,57 whereas the upregulation of MKI67 and
CCNB1 in DTCs in cluster 1 suggests a proliferative phenotype.
It has been hypothesized that subpopulations of DTCs possess
stem cell-like properties.59,60 In this study, we observed that DTCs
in cluster 1 not only displayed high expression of the stem cell
marker, ALDH1A1,20 but also of the proliferation marker, MKI67,
and TACC3, a gene that is involved in promoting stemness and cell
proliferation.13,14 However, functional studies are needed to fully
demonstrate stem cell properties in this subset of DTCs.
We compared the expression status of ESR1 and ERBB2 in DTCs
with the clinical ER and HER2 status of the corresponding primary
tumor. We observed high discordance between ESR1 (40%) and
ERRB2 (43%) status in DTCs vs. the clinical ER and HER2 status of
the corresponding primary tumors, suggesting plasticity of
biomarker status over the course of the disease.61 Previous
studies have also shown discordance in ER (28%62; 53%63) and
HER2 (29–42%64,65) status between DTCs and matched primary
tumors. In contrast, a study using fluorescence in situ hybridiza-
tion analysis showed that HER2 status in DTCs is highly
concordant with that of the corresponding primary tumors.66
Comparison of DTC gene expression with previous CTC results
showed distinct clustering of DTCs vs. CTCs, and both were clearly
distinguishable from normal blood and bone marrow leukocytes.
Further analysis indicated upregulation of stem cell marker
(ALDH1A1) and epithelial–mesenchymal genes (VIM, KRT6A, KRT6B,
KRT18) in DTCs as compared to CTCs. The observed bi-phenotypic
(epithelial and mesenchymal) nature of EPCAM-positive DTCs
isolated by IE/FACS may also be due presence of normal bone
marrow cells (e.g., mesenchymal stromal cells) in the pools of cells
analyzed. Single-cell expression analysis can confirm whether
individual cells express both mesenchymal and epithelial markers.
Limitations of the study include the small sample size, and that
CTCs were not collected from the same patients, as were the DTCs
and primary tumors. Also, we pursued an EPCAM-based isolation
strategy to parallel the approach used in many CTC studies47;
however, we will not capture DTCs lacking EPCAM expression,
such as those undergoing EMT.67
Previously, we studied the feasibility of IE/FACS for isolation of
highly pure CTCs with minimal contaminating hematopoietic cell
content8,9 to facilitate detailed molecular profiling. In this study,
we have extended the use of IE/FACS for direct isolation and in-
depth analysis of DTCs. The ability to isolate CTCs and DTCs using
this approach provides new opportunities to study these two
aspects of cancer metastasis.
CONCLUSIONS
We demonstrate the feasibility of direct isolation and character-
ization of EPCAM-positive DTCs from early breast cancer patients.
Our data revealed molecular heterogeneity among DTCs and
suggested possible genetic divergence of these cells from
corresponding primary tumor. We also detected two subpopula-
tions of DTCs with distinct expression profiles.
METHODS
Patient population and samples
Bone marrow samples were collected from newly diagnosed early breast
cancer patients (clinical stages I–III) who were recruited to participate in a
local study (TIPPING) at the University of California San Francisco (UCSF).
The goal of the TIPPING study, which involved 584 early breast cancer
patients, was to enumerate DTCs and to evaluate their prognostic value.
The results of the TIPPING study will be reported elsewhere. For this
present study, we isolated and profiled small pools of DTCs from 71
TIPPING patients with detectable DTCs. Written informed consent was
obtained from all participants. The study was conducted under a protocol
approved by the UCSF Institutional Review Board.
Bone marrow was collected via a unilateral bone marrow aspiration from
the posterior superior iliac crest while patient was under anesthesia
immediately prior to surgery. Samples were collected in EDTA-containing
tubes and processed within 24 h after bone marrow aspiration (Supple-
mentary Information). Clinical samples were obtained from December
2007 to May 2012. The flow of sample processing is diagrammed in
Supplementary Fig. 2.
DTC enumeration and isolation by IE/FACS
DTCs were enumerated in 4mL of bone marrow and the remaining volume
(median: 7 mLs; range: 2–17mLs) was used for DTC isolation (Fig. 1a). Iron
beads coated with EPCAM monoclonal antibodies were added to bone
marrow samples to enrich for EPCAM-positive cells via magnetic capture.9
Differentially labeled monoclonal antibodies were added to the enriched
sample to distinguish DTCs (nucleated/EPCAM+/CD45−) from bone
marrow leukocytes (nucleated/CD45+/EPCAM−) during cells sorting. Small
pools of DTCs (~20 cells) were isolated via FACS, and samples were stored
−80 °C until further processing.
Copy number profiling
Genome-wide copy number analysis in DTCs was performed as previously
described.9 Briefly, whole-genome amplification (WGA) was performed on
genomic DNA from small pools of IE/FACS-isolated DTCs. The resulting
amplified genomic DNA was used as input for bacterial artificial
chromosome aCGH analysis.
PIK3CA mutation analysis
PCR primers were designed to amplify the regions containing the
complete Exon 9 and Exon 20 of the PIK3CA gene (Supplementary
Information). WGA products were used as inputs for PCR. DNA amplicons
were sequenced using the Sanger method and the entire exons, which
include the PIK3CA mutational hotspot regions on amino acid positions
542, 545, and 1047, were screened for mutations. In DTC samples with
detectable mutations, amplified whole-genome DNA from corresponding
marrow leukocyte was subjected to PIK3CA mutation screening as well.
Point mutations identified were subjected to pathogenic analysis to
determine phenotypic consequences of amino acid changes using the
Functional Analysis through Hidden Markov Models algorithm, following
the guidelines in Catalogue of Somatic Mutations in Cancer (COSMIC) for
pathogenicity annotation.68 Pathogenicity of detected frameshift muta-
tions was predicted using Variant Effect Scoring Tool in the Cancer-Related
Analysis of Variants Toolkit web server.69
Expression profiling
The expression of 64 cancer-related genes in DTCs was analyzed as
previously described.9 Briefly, RT-PCR was performed using a custom
Taqman® Low-Density Array (Applied Biosystems) microfluidic card
containing the 64 Taqman® gene expression assays printed in triplicate
(referred to as aQPCR). To select the optimal gene(s) for normalization, we
used the geNorm algorithm within RealTime StatMiner® to calculate the
gene stability measure (M) for all six candidate genes (ACTB, GAPDH, GUSB,
RPLP0, TFRC, and RPS18). ACTB and RPS18 showed lowest M values
indicating most stable expression across all samples, and therefore were
chosen as references genes.
ESR1/ER and ERBB2/HER status assessment
DTCs with detectable expression (Ct value < 36) of ESR1 and ERBB2 were
considered positive (Supplementary Information). The clinical ER and
HER2 status of corresponding primary tumors were obtained from patients’
medical records.
Statistical analysis
All statistical analyses were carried out using R/Bioconductor software,70
unless otherwise indicated.
Copy number analysis. To determine copy number status (gain/loss/
normal), the aCGH data was processed using circular binary segmentation,
as described previously,9 with some modifications. Details of the methods
for copy number assessment are discussed in the Supplementary
Information.
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Expression analysis. We used the RealTime StatMiner® version 4.2 to
analyze gene expression data. Genes with Cts ≥ 36 were considered
unreliable and were flagged as “not detected”. Unsupervised complete
linkage hierarchical clustering analyses were performed using Euclidean
distance as a similarity measure. Differential expression analysis was
performed using a parametric analysis (Limma) for unpaired samples and a
paired t-test for paired samples. Benjamini–Hochberg method was used to
adjust for multiple comparisons. An adjusted p-value < 0.05 was consid-
ered statistically significant. Relative quantification (RQ) was reported in
the logarithmic scale (log10RQ= log10 2
-ΔΔCt). A log10RQ= 0 means no
differential expression, log10RQ= 1 or −1 means a gene is expressed 10
times or 1/10 as much in the test sample relative to the calibrator sample,
respectively. Two-dimensional clustering was also performed using t-SNE
analysis via the R package Rtnse.71 The 21-gene RSs were computed using
the R package genefu as described in the Supplementary Information.
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